Krishna Institute of Medical Sciences LtdQ1 FY24
Krishna Institute of Medical Sciences Ltd Q1 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹803P/E: 122.9Market Cap: ₹30.5K CrSector: Healthcare Services
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- →KIMS aims to continue its growth trajectory with optimism, critically evaluating new opportunities for expansion and value addition.
- →Existing Telangana and Andhra Pradesh mature assets have headroom for growth; Telangana Secunderabad is at 70% occupancy with room to grow over the next two years.
- →Bed additions planned in FY2025 (e.g., Kondapur expansion) and FY2026 from mature Telangana and AP markets.
- →New hospital facilities like Thane (300 beds) and Nashik (initial 150 operational beds out of capacity for 250-300 beds) expected to contribute to revenue growth.
- →Gradual ramp-up of doctor strength by 12-15 in next 6-9 months to increase patient flow and revenue.
- →Newly acquired Nagpur facility expected to improve EBITDA margin to 10-12% within 6-8 months.
- →Revenue growth driven by incremental clinician additions and phased hospital capacity activation.
- →Expansion focused on consolidating positions in current geographies before entering new ones.
Margin guidance
Category 3- →The company expects to continue growth on the same trajectory with a positive and optimistic outlook.
- →EBITDA margins are projected to improve, with some facilities expecting margin profile changes after new clinicians join.
- →Incremental revenue growth is anticipated from hospital expansions and new doctor recruitments, e.g., a potential Rs. 7-8 Crores incremental revenue at Begumpet.
- →Telangana assets expect high single-digit EBITDA growth, with new specialties and bed capacity expansions supporting this.
- →Consolidated EBITDA margins improved recently, indicating operational efficiency gains.
- →EPS showed strong growth of 15.6% YoY and 22.8% QoQ in recent quarters.
- →Management expects stabilization periods of 6-9 months for new assets, with leadership recruitment as a priority for sustained growth.
- →Long-term ROIC targets around 25% margins and asset turnover of 1-1.25 times per bed.
- →Focus on organic growth from existing mature assets and strategic new acquisitions to drive future profit growth.
3 more insights locked — sign up free to unlock
Fundraise plans
Yes- →The company is investing heavily in growth projects including Bangalore, Nashik, and Thane hospitals.
- →Capex for FY2024 is expected around Rs. 650-700 Crores (250 Crores for Bangalore & Nashik, 250 Crores approx. for Thane if asset-heavy).
- →Discussions are ongoing with institutional investors for an asset-light model for the Thane project to reduce on-balance sheet Capex (~250 Crores reduction if successful).
- →Current net debt is roughly Rs. 300 Crores, with a comfortable debt-to-EBITDA ratio guidance of 1.5 to 1.75 times.
- →The company is generating strong cash flows (~Rs. 400 Crores annually) and plans to deploy this cash for growth, with some possibility of front-loaded debt depending on project structures.
- →Overall, any additional debt or equity raise will depend on finalizing asset-light deals primarily for the Thane project. No explicit mention of new equity fundraising so far.
Order book
- →The transcript provided does not explicitly mention the current or expected order book or pending orders for KIMS Hospitals.
- →The discussion mainly focuses on operational updates, expansions, bed capacity additions, margin improvements, and strategic plans.
- →Key expansions include adding beds in Telangana (from 1200 to ~2000), Andhra Pradesh (from 645 to ~1200), new hospitals planned in Bangalore, Nashik, and Thane slated for FY2025.
- →Nagpur and Sunshine hospital operational and margin progress discussed, but no explicit order book details.
- →Capital expenditure plans mentioned: ₹250 Crores for Thane, ₹350 Crores ongoing for Nashik and Bangalore in FY2024.
- →No direct references to order book values or pending orders are made in the document excerpts provided.
Capex plans
Yes- →Ongoing Capex projects in Bangalore and Nashik, with approximately ₹250 Crores remaining, aiming for operationalization by Q1 FY2025 with initial 150 beds each.
- →Capex of around ₹100 Crores planned for oncology bed additions, gas flow units, mother & child units, and relevant equipment at existing units.
- →Thane hospital project (300 beds) with estimated total cost between ₹400-450 Crores; discussions ongoing for an asset-light model by involving institutional investors to reduce Capex on books by ₹250 Crores.
- →Sunshine Hospital buyout involving Capex for building acquisition ongoing.
- →Vizag hospital expansion (25 beds) operational in FY2024; Sunshine relocation with no new bed addition.
- →Focus on continuous growth with consolidation in current geographies before further expansion.
- →Capex expected to drive margin expansion and capacity growth over 3-6 years with ramp-up plans phased as occupancy improves.
How does Krishna Institute of Medical Sciences Ltd rank vs peers in Healthcare Services?
Pro feature1Krishna Institute of Medical Sciences Ltd
Rev 3Mar 3
See full Healthcare Services sector rankings